Browse studies

Find your next paid study

270 recruiting studies matching your filters

A Phase I Trial of Revumenib in Combination With 7+3 (7 Days of Cytarabine and 3 Days of Daunorubicin) + Midostaurin Induction Chemotherapy for the Frontline Treatment of NPM1 and FLT3 Mutated AML

This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy …

Acute Myeloid LeukemiaAML, AdultAML With Gene Mutations+2 more

Estimated

~$10 – $7,500

Richard Stone, MDNCT06313437

Phase 1

A Phase 1, First in Human Study of Adoptive T Cell Therapy With T Cells Stimulated by Dendritic Cell (DC)/Tumor Fusions in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (AML)

The goal of this research study is to test if the combination of a new T cell therapy (dendritic cell (DC) / acute myeloid leukemia (AML) primed T cells), vacc…

Acute Myeloid LeukemiaAcute Myeloid Leukemia, in Relapse

Estimated

~$10 – $7,500

David AviganNCT07374029

Phase 1

Olutasidenib Single Agent as Maintenance Therapy in IDH1mut AML After Induction and Consolidation

Treatment with olutasidenib for isocitrate dehydrogenase 1 (IDH1) mutant acute myeloid leukemia (AML) after completion of traditional intensive induction/conso…

Acute Myeloid Leukemia

Estimated

~$10 – $6,250

Virginia Commonwealth UniversityNCT07130695

Phase 2

A Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Venetoclax Plus Decitabine in Patients With AML Who Are Ineligible for Intensive Induction Therapy

The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete R…

Acute Myeloid Leukemia (AML)

Estimated

~$10 – $8,750

Bio-Path Holdings, Inc.NCT02781883

Phase 1

CROSSCHECK-001: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants …

High-risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)AML - Acute Myeloid Leukemia+1 more

Estimated

~$10 – $8,750

Crossbow Therapeutics, Inc.NCT06994676

Phase 1

IMetelstat and Azacitidine With or Without Venetoclax GIveN in rElapsed Acute Myeloid Leukemia (IMAGINE Trial)

IMAGINE is a two-part trial to evaluate the safety and preliminary efficacy of imetelstat in combination with azacitidine with or without venetoclax in patient…

Relapsed Acute Myeloid Leukemia

Estimated

~$10 – $7,500

Douglas TremblayNCT07320235